Ultragenyx agrees to sell rare pediatric disease priority review voucher for $210 million
Bitget2026/10/07 12:32Ultragenyx entered a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher for USD 210 million. The voucher was awarded on FDA clearance of GENGLYCOS (DTX401) for glycogen storage disease type Ia. Proceeds are expected to provide non-dilutive funding for pipeline development, supporting the company’s profitability plans. Closing depends on customary conditions, including expiration of the Hart-Scott-Rodino waiting period. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ultragenyx Pharmaceutical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610070830PRIMZONEFULLFEED9841089) on October 07, 2026, and is solely responsible for the information contained therein.
- Ultragenyx entered a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher for USD 210 million.
- The voucher was awarded on FDA clearance of GENGLYCOS (DTX401) for glycogen storage disease type Ia.
- Proceeds are expected to provide non-dilutive funding for pipeline development, supporting the company’s profitability plans.
- Closing depends on customary conditions, including expiration of the Hart-Scott-Rodino waiting period.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Kalshi Submits Proposal for Perpetual Oil Contracts to the CFTC
BUZZ - Halozyme shares rise after winning a case against Merck's injectable Keytruda in a Dutch court
October 7 – Halozyme (HALO.O) shares rose 1.4% pre-market to $111.24. Halozyme announced it had obtained an injunction from a Dutch court (link), prohibiting Merck MRK.N from manufacturing, selling, and importing subcutaneous Keytruda in eight European markets. The court determined that Merck had infringed Halozyme’s EP622 patent and rejected Merck’s claims that the patent was invalid. Halozyme stated that patients will still have access to the intravenous version of Keytruda, which is not affected by the injunction. As of the close of the previous trading day, HALO shares have risen 62% this year. (For non-English speakers, Reuters automatically translates its reports into several languages. Due to possible errors or missing context in automated translations, Reuters does not guarantee the accuracy of such translated texts, which are provided for readers’ convenience only. Reuters assumes no liability for any damages or losses caused by use of the automated translation function.)
BUZZ-KeyBanc upgrades Corteva rating to "Overweight"; stock price rises
On October 7, KeyBanc upgraded the rating of agricultural technology company Corteva Inc (CTVA.N) from "Sector Weight" to "Overweight." CTVA rose 1.6% in pre-market trading to $14.1. The brokerage pointed out that new product launches, cost reductions, and improvements in farmers' economic conditions will be strong growth drivers for 2028-2029. The company’s ample cash reserves enable it to flexibly fund growth initiatives, stock buybacks, and potential acquisitions. Out of 23 brokerages, 16 have given the stock a "Buy" or higher rating, and 7 have rated it "Hold." The median target price is $18. As of the previous trading day's close, the stock had gained 38.3% year to date.
Antofagasta’s Centinela strike adds copper supply risk
Crypto prices
More
